These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8081411)

  • 1. CYP2D6 genotyping and the association with lung cancer susceptibility.
    Wolf CR; Smith CA; Bishop T; Forman D; Gough AC; Spurr NK
    Pharmacogenetics; 1994 Apr; 4(2):104-6. PubMed ID: 8081411
    [No Abstract]   [Full Text] [Related]  

  • 2. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk.
    London SJ; Daly AK; Thomas DC; Caporaso NE; Idle JR
    Pharmacogenetics; 1994 Apr; 4(2):107-8. PubMed ID: 8081412
    [No Abstract]   [Full Text] [Related]  

  • 3. Debrisoquin oxidation genotype and susceptibility to lung cancer.
    Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
    Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association.
    Caporaso N; DeBaun MR; Rothman N
    Pharmacogenetics; 1995; 5 Spec No():S129-34. PubMed ID: 7581482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation of CYP2A6, smoking, and risk of cancer.
    London SJ; Idle JR; Daly AK; Coetzee GA
    Lancet; 1999 Mar; 353(9156):898-9. PubMed ID: 10093988
    [No Abstract]   [Full Text] [Related]  

  • 7. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
    Stücker I; Cosme J; Laurent P; Cenée S; Beaune P; Bignon J; Depierre A; Milleron B; Hémon D
    Carcinogenesis; 1995 Nov; 16(11):2759-64. PubMed ID: 7586196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CYP2D6 genotype determination].
    Brøsen K
    Ugeskr Laeger; 1993 Nov; 155(46):3779-80. PubMed ID: 8256376
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
    Beyeler C; Armstrong M; Bird HA; Idle JR; Daly AK
    Ann Rheum Dis; 1996 Jan; 55(1):66-8. PubMed ID: 8572738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility.
    Buchert ET; Woosley RL; Swain SM; Oliver SJ; Coughlin SS; Pickle L; Trock B; Riegel AT
    Pharmacogenetics; 1993 Dec; 3(6):322-7. PubMed ID: 8148873
    [No Abstract]   [Full Text] [Related]  

  • 13. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
    Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL
    Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
    Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
    Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of phenotype and genotype for CYP2D6.
    McLeod HL
    Clin Pharmacol Ther; 1994 Oct; 56(4):463-4. PubMed ID: 7955809
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular genetics of lung cancer.
    Carbone DP; Minna JD
    Adv Intern Med; 1992; 37():153-71. PubMed ID: 1348393
    [No Abstract]   [Full Text] [Related]  

  • 18. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
    Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
    J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
    Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
    J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.